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Mario Lapecorella, Antonio Tabilio, Alessandro Lucchesi,
Mariasanta Napolitano, Marianna Colagrande, Mauro Di Ianni
and Guglielmo MarianiThe discovery of the Janus kinase 2 Val617Phe mutation
has brought new insights into the development of
myeloproliferative disorders; however, the pathogenesis of
essential thrombocythemia and its related thrombotic
complications has not been completely understood.
Although the Janus kinase 2 Val617Phe mutation confirms
the initially suspected clonal character of the disease,
factors influencing clonal transformation and expansion in
the bonemarrow have not been fully detected. Furthermore,
patients affected by essential thrombocythemia who are
carriers of the Janus kinase 2 Val617Phe mutation show a
higher incidence of venous thromboembolism both before,
and at the time of diagnosis, comparedwith noncarriers, and
recent evidence of splanchnic and cerebral vein thrombosis
in carriers of the Janus kinase 2 Val617Phe mutation has
been reported. The intake of oral contraceptives is a strong
and independent risk factor for venous thromboembolism.
In addition, in-vitro tests showed both an altered primary
haemostatic plug formation and enhanced platelet
aggregation in patients taking such drugs. Little is known,
though, about the influence of steroid hormones on bothopyright © Lippincott Williams & Wilkins. Unauth
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Essential thrombocythemia (ET) belongs to the larger
group of myeloproliferative disorders (MPDs), a set of
haematological malignancies globally characterized by
clonal haematopoiesis [1]. Clonal haematopoiesis in
patients with MPDs is supported by a genetically trans-
formed mutant clone, which retains the capacity to
differentiate across multiple cell lineages. Several studies
have assessed the nature of clonal haematopoiesis in this
group of haematological diseases, each using different
techniques including X chromosome inactivation studies
[2], cytogenetic studies [3,4] and mutation screening
studies. The latter studies have been of crucial import-
ance in the last few years since the discovery of a unique
acquired clonal mutation in the Janus kinase (JAK)2.
JAK2 is a cytoplasmatic tyrosine kinase directly involved
in survival, proliferation and maturation of erythroid
progenitors by binding to erythropoietin receptors. Bind-
ing of erythropoietin to its receptor results in phosphoryl-
ation and activation of JAK2 and phosphorylation of the
eryththropoietin receptor itself. The phosphorylated
sites become recruitment sites for a family of cytoplas-
matic proteins known as signal transducers and activatorsof transcription (Stats), which activate the proliferation
and differentiation signal. A single valine to phenyl-
alanine substitution at position 617 occurring in the
JH2 domain of JAK2, which is involved in inhibition of
the kinase activity, leads to a gain of function of the
JAK2–Stat5 pathway and such effect is enhanced in
the cell lines expressing the erythropoietin receptor
[5]. The mutation is detectable in approximately 70–
90% of patients with polycythemia vera, whereas patients
affected by essential thrombocythemia and idiopathic
myelofibrosis (IMF) show a positive rate of about 50%
with available techniques [5]. Despite so much progress,
many issues remain open in the field of MPDs. One
comes from the observation that, particularly in essential
thrombocythemia, the mutation detected on peripheral
blood leukocytes does not exactly reflect in terms of
allelic ratio the number of colonies carrying the mutation
in the bone marrow [6]. According to Lippert at al. [7], the
allelic ratio of the mutation, defined as the signal of each
allele divided by the sum of signals for both alleles,
increases in case of active haematopoiesis and the expres-
sion levels of the JAK2 mRNA differ both in different
stages of the disease and among different MPDs. Factorsorized reproduction of this article is prohibited.
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and thus the rate of clonal haematopoiesis in the bone
marrow remain largely unknown and mutation carriers
with similar bone marrow biopsy pattern show different
clinical course, suggesting that, given the presence of
a clonal disease, other events are needed for disease
progression [8].
Another unsolved issue in MPDs deals with the patho-
genesis of the related thrombotic and haemorrhagic
manifestations, the former prevailing on the latter in this
group of malignancies. Arterial thrombotic events, both
cardiovascular and cerebrovascular, microcirculatory
disturbances such as erythromelalgia and venous throm-
boembolism (VTE) are common in essential thrombo-
cythemia. The discovery of the JAK2 Val617Phe
mutation has cast new light on this burning issue.
Evidence exists that enhanced platelet activation plays
a key role in the pathogenesis of thrombosis in MPDs,
particularly essential thrombocythemia and polycythe-
mia vera, which is due to interactions between platelets
and leukocytes [9]. The release of procoagulant and
inflammatory cytokines from activated leukocytes as
well as tissue factor containing microparticles would
promote the formation of platelets–leukocytes aggre-
gates, enhancing the basic coagulation threshold with
consequent detectable endothelial damage [10].
It is of special clinical importance that patients with
JAK2-positive essential thrombocythemia have an
increased incidence of VTE compared with a similar
mutation-negative population [11]. The role of increased
platelet and leukocytes activation as a thrombogenic
mechanism in patients with JAK2-positive essential
thrombocythemia was successfully investigated in 2006
by Arellano-Rodrigo et al. [12], and more recently con-
firmed by Robertson et al. [13]. Nevertheless, data are
insufficient to explain some peculiar features of VTE
in MPDs such as the occurrence in unusual sites and
before the disorder is clinically overt, suggesting that, in
accordance with its multifactorial nature, other events
may be necessary to produce the thrombotic event.
In the present article, we describe the case of a 30-year-
old woman who came to our attention for a severe
splanchnic deep vein thrombosis (DVT), which occurred
after a 5-month course of therapy with a third generation
steroid hormone preparation. She was diagnosed to be
affected by essential thrombocythemia and to carry the
JAK2 Val617Phe mutation. A possible influence of oral
contraceptives intake on both essential thrombocythemia
progression and the pathogenesis of thrombotic events
is discussed.
Case report
A 30-year-old woman with both personal and familial
negative history for VTE was admitted to our departmentopyright © Lippincott Williams & Wilkins. Unauthofor an almost complete thrombotic obstruction of the
splenoportal axis and a superior mesenteric vein throm-
bosis. Five months before the hospital admission, she had
started the intake of a third generation oral contraceptive
(Yasmin, from Shering, Milan, Italy; 30mg ethinylestra-
diol and 3 mg drospirenone). At the start of the treatment,
coagulation screening including blood cell count,
prothrombin time (PT), activated partial thromboplastin
time (aPTT), fibrinogen and antithrombin was normal.
Three days before admission, she had suffered from
abdominal pain not responsive to intramuscular domper-
idone administration. Ultrasonography and a computed
tomographic scan revealed a thrombotic occlusion invol-
ving the splanchnic district deep veins. She was then
referred to our centre for a better definition of the clinical
picture and treatment. A duplex ultrasonography con-
firmed the absence of blood flow in the splenoportal axis.
Blood samples revealed an increased platelet count
(964 109/l). Therefore we performed a bone marrow
biopsy that showed a striking abundance of very large
megakaryocytes, often forming clusters. As such exam-
ination revealed essential thrombocythemia coexisting
with an unusual site of thrombosis, we screened our
patient for both the JAK2 Val617Phe mutational status
and the main thrombophilic conditions in order to exactly
define a prothrombotic state. Moreover, routine tests
and tumour markers were carried out in order to exclude
other underlying diseases. Soon after the confirmation
of thrombosis, unfractionated sodium heparin was
administered at the dose of 25 000 IU/day, followed
by oral anticoagulation with warfarin, maintaining
the prothrombin time international normalized ratio
(PT-INR) between 2 and 3 (target 2.5). Hydroxyurea
was also started for essential thrombocythemia treatment,
modulating the daily dose in order to achieve a platelet
count lower than 600 109/l. While on therapy, periodic
abdominal ultrasonography showed a progressive resol-
ution of the portal thrombosis until complete recanaliza-
tion, and a stable platelet count was obtained within
1 month.
Materials and methods
Venous blood from the fasting patient was drawn into
siliconized glass tubes containing 3.8% trisoduim citrate
(1 : 9 v/v). Plasma obtained by centrifugation (2000 g for
20 min at room temperature) was snap frozen in liquid
nitrogen and stored at 808C within 2 h after collection.
Venous blood for DNA analysis was collected in tubes
containing ethylenediaminetetraacetic acid. Anticardio-
lipin and antib2 glycoprotein 1 antibodies were measured
on serum samples stored at 208C until analysis.
Antithrombin (HemosIL antithrombin; Instrumentation
Laboratory Spa, Milan, Italy), Protein C (HemosIL
Protein C; Instrumentation Laboratory) and factor VIII
(HemosIL factor VIII deficient plasma; Instrumentationrized reproduction of this article is prohibited.
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methods. Activated protein C resistance (APCR) was
performed by a standard commercial assay (Chromo-
genix, Mo¨lndal, Sweden). Free protein S was carried
out by an immunological method (HemosIL free protein
S; Instrumentation Laboratory). Lupus anticoagulant
(HemosIL LAC Screen/LAC Confirm; Instrumentation
Laboratory), anticardiolipin and antib2 glycoprotein 1
antibodies (Diamedix Corporation, Miami, Florida,
USA) were detected using commercial kits. Basal homo-
cysteine was determined using an immunological fluor-
escence polarization-based assay (Abbott AxSYM System;
Abbott Laboratories, Abbott Park, Illinois, USA).
Genotype analysis for the G1691A mutation of the factor
V gene, the G20210A mutation of the prothrombin gene
and the C677T mutation of the methylenetetrahydrofo-
late reductase (MTHFR) gene were performed using a
real time polymerase chain reaction technique (Applied
Biosystem, Melbourne, Australia).
The JAK2 Val617Phe mutation was detected using a
DNA microchip diagnostic platform (Nanochip Molecular
Biology Workstation, Nanogen Inc., San Diego, CA, USA)
[14].
Tumour markers (CEA, CA 125, CA 19-9, CA 15-3, AFP)
were dosed using a chemiluminescent immunologic
microparticle assay (CMIA Architect System; Abbott
Laboratories).
Two replicates were analysed for each test, and the mean
value was calculated. Furthermore, all parameters were
performed repeatedly on several occasions with similar
results.
Results
Coagulation and genotypic parameters are shown in
Table 1. Genetic analysis revealed homozygosity foropyright © Lippincott Williams & Wilkins. Unauth
Table 1 Plasma levels at the time of hospital admission
Parameter Result Normal range
Platelet count(109/l) 964 130–400
Antithrombin (%) 90 85–125
Factor VIII (%) 117 70–120
Protein C activity (%) 72 70–120
Free protein S (%) 64 53–109
Normalized activated protein C sensitivity ratio 0.83 <0.95
Lupus anticoagulant 1.04 0.8–1.2
Anticardiolipin antibody IgM (U/ml) 4.1 <10
Anticardiolipin antibody IgG (U/ml) 3.9 <10
Antib2 glicoprotein 1 IgM (U/ml) 3.1 <10
Antib2 glicoprotein 1 IgG (U/ml) 3.7 <10
V617F JAK2 mutation Heterozygosis Absent
Factor V Leiden mutation Absent Absent
G20210 A prothrombin mutation Absent Absent
C677T MTHFR mutation Homozygosis Absent
Homocysteine (mmol/l) 11.4 <15
JAK, Janus kinase; Ig, immunoglobulin; MTHFR, methylenetetrahydrofolate
reductase.the C677T mutation in the MTHFR gene with normal
homocysteine plasma levels.
As mentioned, bone marrow biopsy revealed an increased
number of very large clustering megakaryocytes. This
finding, along with the platelet count and the presence
of the JAK2 Val617Phe mutation in absence of any other
bone marrow finding related to polycythemia vera or
IMF, meets the 2008 WHO diagnostic criteria of essential
thrombocythemia. The JAK2 Val617Phe mutation detec-
tion was positive with an allelic ratio of 11.6, which is in
accordance with a lower than 50% value in the heterozy-
gous mutational status. All other routine tests were normal.
Discussion
There was a statistically significant increased incidence
of thrombosis in a subset of patients with essential
thrombocythemia and who were carriers of the JAK2
Val617Phe mutation. Portal and mesenteric thrombosis,
as well as cerebral DVT are the most common occur-
rences and the mutation can be now considered a risk
factor for such events [15]. The pathogenetic mechanism
of the increased thrombophilic state associated with the
mutation is not clear. An intriguing observation relates to
a recent retrospective study by De Stefano et al. [16], who
detected the mutation in a significant proportion of
patients with splanchnic and cerebral DVT without overt
MPD, suggesting that the number of platelets is not a
major determinant of thrombosis. This is in accordance
with the conclusions in the study conducted by Harrison
et al. [17], in which a comparison analysis of thrombotic
and haemorrhagic events between two large groups
of patients with essential thrombocythemia treated
with hydroxyurea and anagrelide, respectively, was
performed. Results revealed a statistically significant
number of thrombotic and haemorrhagic events in the
anagrelide-treated group, indicating that not only the
number of platelets but also their activation status is
affected by different cytoreductive strategies and that
the choice of drug must take into account both the clinical
history and the cardiovascular risk factors.
The intake of oral contraceptives is a strong and inde-
pendent risk factor for VTE [18,19] and a large number of
trials have been conducted to assess the rate of throm-
botic risk connected with their use. Several studies have
successfully estimated the thrombotic risk deriving from
the interplay between oral contraceptives of different
generations and inherited or acquired thrombophilias.
In addition, the role of platelet functional status in the
pathogenesis of VTE during oral contraceptives con-
sumption is emerging. Platelet aggregation has been
shown to be influenced in vitro by 17beta-estradiol and
medroxyprogesterone acetate in postmenopausal women
[20], whereas different activation rates have been
reported during the ovarian cycle [21]. To clarify the
influence of sex steroids on platelet function as a possibleorized reproduction of this article is prohibited.
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Roell et al. [22] set up a platelet aggregation cross-sec-
tional trial with five groups of healthy young women with
and without intake of oral contraceptives. In the first two
groups, those not taking any oral contraceptives, platelets
aggregation was evaluated in the follicular phase and in
the luteal phase, respectively. The remaining three
groups consisted of women taking oral contraceptives
of second and third generation. Women belonging
to the third and the fourth groups were users of oral
contraceptives with a similar progestogen component
but different estradiol dose, which was lower in the
fourth group. In the last group, women were taking oral
contraceptives with a different progestogen, that is, with
antiandrogenic effect. The authors demonstrated that
platelet function is altered in two phases of the ovarian
cycle, being activated in the luteal phase compared with
the follicular phase. More interestingly, platelet aggrega-
tion was enhanced during oral contraceptive intake and
the major determinant of the activation status was the
progestogen moiety with the antiandrogen components
exerting the highest effect in the last group [22]. Experi-
mental data are in accordance with clinical reports of
thrombotic episodes in women taking progestogen-only
oral contraceptives whose prothrombotic potential,
although they are recommended in women with a
personal history of VTE, has never been investigated
in large trials [23]. The molecular basis of platelet aggre-
gation during steroid intake is a grey area that has been
poorly evaluated and only one study [24] has been
performed to outline a steroid hormone receptor profile
on megakaryocytes and platelets in humans.
Our patient took for 5 months a drug belonging to the third
generation of oral contraceptives, which were commercia-
lized in an attempt to reduce some androgenic effects of
second-generation oral contraceptives and have been
shown to be more prothrombotic than those of the second
generation [25]. The thrombotic risk of oral contraceptives
in association with the JAK2 mutation has never been
evaluated so far and one single report exists in the literature
of a DVT episode with such a combination [26]. As
mentioned, third generation oral contraceptives with anti-
androgenic properties produce the strongest effect on
platelet aggregation in normal individuals. We suppose
that this effect can be enhanced in platelets of JAK2-
mutation carriers in which a higher baseline activation
status has been demonstrated [12]. This hypothesis is
supported by the finding of no other thrombophilia in
our patient. Despite detection of homozygosity for the
C677T mutation of the MTHFR gene, homocysteine
levels were normal in our patient and studies [27] per-
formed on this topic did not find any association between
hyperhomocysteinemia and thrombotic events in MPDs.
As our patient showed a sudden onset of clinically
symptomatic essential thrombocythemia during a shortopyright © Lippincott Williams & Wilkins. Unauthocourse hormonal therapy, we therefore wondered if the
oral contraceptive use might have contributed to the
progression or establishment of the underlying haema-
tological disorder beyond the thrombotic episode. We do
not know, of course, if the JAK2 mutation was present
before the hormonal treatment started, but the short
course up to the clinical evidence of the disease deserves
some consideration. In a recent prospective observa-
tional study, Gale et al. [28] showed no significant change
in the mutant JAK2 expression in a large number of
patients affected by essential thrombocythemia fol-
lowed over a median period of 4 years, demonstrating
that a minor number of mutated clones that have arisen
on a polyclonal background can remain stable unless
other precipitating events occur to determine disease
progression. Interestingly, experimental evidence has
proved that progestogens are able to constitutively
induce Stat3 transcriptional activation in breast cancer
cells and that this effect is mediated by JAK1 and JAK2,
whose abolishment activity results in the suppression of
all medroxyprogesterone acetate effects on cancer
growth [29]. A possible contributing role of steroid
hormones, progestins specifically, in the molecular
mechanism of essential thrombocythemia might be
taken into account considering that Stat3 is progesterone
dependent. It is noteworthy that Stat3 and Stat5 phos-
phorylation is enhanced in essential thrombocythemia
and polycythemia vera, and that such activation rate has
been demonstrated not to be influenced by the JAK2
Val617Phe mutation [30]. Furthermore, Stat3 has been
shown to be constitutively active in polycythemia vera
[31]. Such observations reinforce the idea that clonal
transformation in MPDs results from a sum of stepping
up events.
In conclusion, given the increased thrombotic risk in
carriers of the JAK2 Val617Phe mutation compared with
noncarriers, the mechanism by which the mutation
results in a prothrombotic state is largely unknown, even
though platelet activation seems to play an important
role. Its better definition will contribute to clarify the
mechanism of thrombophilia and the complex relation-
ships between genetic and environmental factors. The
onset of a clinically symptomatic haematological malig-
nancy after a short course of oral contraceptives intake
suggests that great caution should be paid before admin-
istering oral contraceptives in carriers of JAK2 Val617Phe
mutation. As we live in an era in which we debate the
usefulness and expensiveness of thrombophilic screen-
ing, our report outlines the emerging importance of the
JAK2 Val617Phe mutation testing, a matter which has
been poorly evaluated so far [32].References
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